AIM ImmunoTech

Hemispherx Biopharma is a small American pharmaceutical company that produces the drug Ampligen. Corporate headquarters are in Philadelphia, PA and the main manufacturing and research facility is in New Brunswick, NJ. In addition to Ampligen, Hemispherx produces Alferon N Injection® and Alferon® LDO (Low Dose Oral). To date, only Alferon N Injection® has FDA approval. Ampligen and Alferon® LDO are not FDA-approved and are considered experimental.

In Feb 2016, Dr. William Carter, then Chairman and CEO, was terminated by the board of directors of Hermispherx Biopharma, who cited that part of the reason was a strong financial austerity plan. William M. Mitchell, M.D., Ph.D. was promoted in house as his replacement.

In June 2016, the law suit was resolved between Dr. Carter and Hemispherx regarding the wrongful termination claim. As part of the settlement, the intellectual property rights, including the patent for Ampligen and Alferon, are irrevocably assigned to to Hemispherx.

Management

 * Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary & General Counsel
 * Adam Pascale, CPA - Chief Financial Officer
 * David R. Strayer, M.D. - Chief Scientific & Medical Officer
 * Wayne Springate - Senior Vice President of Operations

Board of Directors

 * William M. Mitchell, M.D., Ph.D. - Chairman of the Board
 * Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
 * Peter W. Rodino III, Esq.- Lead Director

Online presence

 * Website
 * SEC filings - Hemispherx Biompharma

Talks and interviews

 * 2016, Small Cap Nation - ME/CFS (Updated) (Thomas Equels)

Learn more

 * Wikipedia - Hemispherx Biopharma
 * Wikipedia - Rintatolimod
 * http://simmaronresearch.com/2016/05/hemispherx-ampligen-approval-chronic-fatigue-syndrome-top-priority/
 * 2016, Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It
 * 2016, Executive Informational Overview by Crystal Research Associates
 * 2016, Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement (see also NIH Post-Infectious ME/CFS Study)
 * 2016, Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear
 * 2014, Investor's post about HEB's rocky history